OncoSil Medical
Renzo G. DiCarlo is a seasoned professional in the life sciences and pharmaceuticals sectors, currently serving as Vice President of Development at Alexion Pharmaceuticals, Inc., where leadership focuses on optimizing R&D clinical trials and product development. DiCarlo holds multiple advisory roles, including positions on various boards such as the Clinical Education Alliance and OncoSil Medical, providing strategic insights and support for innovative cancer therapies. With an extensive background as the former CEO of BioPharma Services Inc., DiCarlo's expertise spans across global logistics and equity partnerships, highlighted by contributions to the Canada-Belgium Committee and the Canadian International Fashion Film Festival. Renzo G. DiCarlo's educational credentials include an MBA in Strategy from Queen's University and a Global Masters in Management from The London School of Economics and Political Science.
This person is not in any teams
This person is not in any offices
OncoSil Medical
OncoSil Medical is a global medical device company focused on Interventional Oncology. Our mission is to improve the outcomes by utilising the selected and targeted intratumoural placement of Phosphorous-32 (³²P) Microparticles in combination with chemotherapy. OncoSil Medical’s lead product, OncoSil™, is a brachytherapy device which has received CE Marking approval, providing marketing authorisation in both the EU and the UK. The device is approved for use in New Zealand, Hong Kong, Switzerland, Turkey and Israel. OncoSil™ is designated as a breakthrough device in both Europe and the United States¹. We believe in our technology and its ability to have a truly positive impact in Oncology. OncoSil™ technology is not available in all geographies. If you are a healthcare professional, please refer to our website for information about our technology and indications. Website link: oncosil.com References: 1. US Food and Drug Administration (FDA) Breakthrough Device Designation. March 2020. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020.